Drug Profile

JW 2286

Alternative Names: JW-2286; ST-2286

Latest Information Update: 07 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator C&C Research Laboratories
Developer JW Pharmaceutical
Class Antineoplastics; Small molecules
Mechanism of Action STAT3 transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

06 Jan 2025 Phase-I clinical trials in Solid tumours (In volunteers) in South Korea (PO) (JW Pharmaceuticals pipeline, October 2024) (NCT06703710)
02 Dec 2024 JW Pharmaceutical plans a phase I trial (In volunteers) in South Korea (PO), in January 2025 (NCT06703710)
28 Oct 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in South Korea (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com